لماذا يرتفع سعر سهم ELI LILLY AND CO؟
المتفائلون يقولون
Pivotal trial efficacy
Analyst highlights pivotal trial results showing retatrutide produced weight loss comparable to bariatric surgery with lower discontinuations and a new lower-dose arm that may improve tolerability and broaden patient adoption.
Oral GLP‑1 market expansion
Analyst's model indicates oral GLP‑1 medicines could substantially expand the obesity treatment market as many physicians are willing to prescribe oral options and treat new or restarting patients.
Franchise and pipeline momentum
Analyst's Outperform view is supported by a strengthening diabetes franchise, recent drug approvals, and an expanding oncology pipeline that together should drive durable revenue and earnings growth.
Safety and tolerability risks
Durability of treatment effects and potential liver and other safety risks, plus observed adverse events and elevated discontinuations in some trials, could undermine confidence and pressure the stock.
Competitive and pricing pressure
Pricing declines in the obesity market or loss of share to competitors and execution shortfalls with current or pipeline assets could compress margins and weaken valuation.
Data and launch execution uncertainty
Unclear prescription data capture across channels and intense investor comparisons of launch trajectories create uncertainty about true market uptake and could increase stock volatility.
